Pasireotide vs Teriparatide
Overview
Pasireotide is primarily a hormonal peptide, while Teriparatide is used for bone & joint.
This page compares Pasireotide and Teriparatide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pasireotide | Teriparatide | |
|---|---|---|
| Category | Hormonal | Bone & Joint |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) | 20 mcg |
| Frequency | Twice daily (SC formulation) or every 4 weeks (LAR formulation) | daily |
| Reported benefits | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism | Bone density increase, osteoporosis treatment, fracture prevention |
| Reported side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) | Dizziness, leg cramps, nausea |
Key differences
Primary use. Pasireotide is categorised under Hormonal, while Teriparatide falls under Bone & Joint. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Pasireotide: FDA-approved. Teriparatide: FDA-approved.
Dosing. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)). Teriparatide is typically dosed at 20 mcg (daily).
Can you stack them?
Some protocols combine peptides, but stacking Pasireotide and Teriparatide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pasireotide and Teriparatide?
- Pasireotide is primarily a hormonal peptide, while Teriparatide is used for bone & joint. Pasireotide is FDA-approved for one or more indications, whereas Teriparatide is FDA-approved for one or more indications.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- What is Teriparatide used for?
- FDA-approved bone builder.
- Can you take Pasireotide and Teriparatide together?
- Some users combine peptides within a single protocol, but stacking Pasireotide and Teriparatide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pasireotide or Teriparatide FDA-approved?
- Pasireotide is FDA-approved for one or more indications. Teriparatide is FDA-approved for one or more indications.
Read the full articles
- Pasireotide — full monograph: mechanism, research, dosing & references
- Teriparatide — full monograph: mechanism, research, dosing & references